<DOC>
	<DOCNO>NCT03102203</DOCNO>
	<brief_summary>To evaluate efficacy multi-modality magnetic resonance quantitative parameter evaluate treatment effect high-grade glioma , provide new biomarkers establishment new diagnostic criterion identification true pseudoprogression high-grade glioma .</brief_summary>
	<brief_title>Differentiation Progression From Treatment Effects High-Grade Gliomas : A Clinical Trial With Multimodality MR Imaging</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<criteria>1 . Patients highgrade glioma confirm pathology treat concurrent chemoradiotherapy ; 2 . Written inform consent obtain . 1 . Patients suitable enhanced MRI scanning patient ; 2 . Patients finish followup concurrent chemoradiotherapy MR scanning .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>